Return
Maximizing public health benefits: Policy perspectives on coverage and cell-based influenza vaccines in the US
V
Văn Hùng NguyễnJ
Joaquin F. Mould-Quevedo* DOI:10.1080/21645515.2026.2640759.png)
Abstract
En 中文
Cell-based influenza vaccines can increase vaccine effectiveness by avoiding egg adaptations associated with traditional egg-based manufacturing techniques. This study evaluated the impacts of switching from use of an egg-based trivalent influenza vaccine (TIVe) to a cell-based vaccine (TIVc) for vaccination of individuals <65 y of age in the US. We used a dynamic age-stratified susceptible-exposed-infectious-recovered model combined with an age-structured decision tree model to compare the health and economic impacts of using TIVc in individuals <65 y combined with adjuvanted trivalent influenza vaccine (aTIV) in older adults (≥65 y) with two baseline scenarios: 1. vaccination of all individuals with TIVe; 2. vaccination of individuals <65 y with TIVe and ≥65 y with aTIV. Use of TIVc+aTIV resulted in substantial reductions in influenza burden across all vaccine coverage levels evaluated, with 8.5 million cases, 127,000 hospitalizations, and 19,000 deaths averted compared with TIVe at 65% coverage. The combination of TIVc and aTIV was cost-saving compared with either baseline scenario, irrespective of vaccine coverage level. Analysis by age group showed that TIVc+aTIV was either cost-effective or cost-saving across all pediatric and adult age groups, with greatest direct cost benefits seen in adults 50–64 y. Overall, our findings support the preferential use of TIVc over TIVe in individuals <65 y in vaccination programs, along with inclusion in programs together with an enhanced vaccine in adults ≥65 y.
Keywords:
Cost-effectiveness
ICER
cell-based influenza vaccine
egg-based influenza vaccine
vaccine policy
TIVc
aTIV
Journal
H
IF:
0
Papers:
6
Citations:
0
